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A Study of Sensitivity of Esophageal Cancer to 
Anticancer Agents 
NORIO MATSUMOTO 
The Second Department of Surgery, Yamaguchi University School of Medicine 
(Director: Prof. Dr. KOICHI ISHIGAMI) 
The results of surgical treatment of esophageal cancer has been improved. But now the 
prognosis is not so good. To make the supplementary chemotherapy combined with the surgical 
treatment more effective, the sensitivities of 25 cases of esophageal cancer to three kinds of antican-
cer agents were investigated by IN AS (Inhibition of Nucleic Acid Synthesis) method. 
Original tumors of esophageal cancer were transplanted into nude mice, and the sensitivities 
of xenografts in nude mice of first generation were investigated in the same way. The following 
results were obtained ; 
1) Ten cases out of 25 (40箔） were sensitive to Bleomycin (BLM), 9 cases out of 25 (36%) to 
Cisplatin (CDDP), 9 cases out of 16 (56.35ぢ） to 5-Fu. 
2) As regarding the results of sensitivity test analysed according to the types of roentgenological 
findings, macroscopical findings, histological findings, a factors, n factors, ly factors, and v factors, 
there were no correlations. 
3) The sensitivity of the metastatic lymph nodes to CDDP was higher than that of main lesions 
(P < 0.10), and the sensitivity of the peripheral portions of tumor to CDDP was higher than that 
of central portions (P < 0.05). 
4) Original tumors of human esophageal cancer were transplanted into nude mice and 5 cases 
out of 10 (50渚） were successfully transplanted primarily. 
5) CDDP (3 mg/kg) and 5・Fu(25 mg/kg) were administered to nude mice by intraperitoneal , 
injection and after two hours, CD DP levels in the tumors were O. 27 ± O. 05 μg/ g and 5・Fulevels 
were 4. 05土0.35 μg/g. 
6) The sensitivities of corresponding xenografts in nude mice to BLM and CDDP had atendency 
to be higher than those of the original tumors of esophageal cancer. 
Key words: Esophageal cancer, Sensitivity test, Bleomycin, Cisplatin, 5-Fu. 
索引語：食道癌，感受性試験，ブレオマイシン，シスプラチン，ファイブ・エフユー．
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度を参考とし， BLM および CODP においては，
control, 0. 1 μg/ml, 1 μg/ml, 10 μg/ml とした．ま














II) COOPおよび 5Fu の濃度：雄性家兎（体重
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BLM, CDDP, 5-Fu 3 
BLM, CDDP 1 
BLM, 5-Fu 1 
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9 ( 60) 24 15 9 (38) 24 14 10 (42) 計
62 日外宝第55巻第1号（昭和61年1月）
表9 ly因子と制癌剤感受性
BLM CDDP 5-Fu 
＋ 計 十 計 ＋ 計
1 y (+) 4 (24) 13 17 7 (41) 10 17 7 (64) 4 11 
1 y （ー） 4 (67) 2 6 1 (17) 5 6 1 (33) 2 3 
計 8 (35) 15 23 8 (35) 15 23 8 (73) 6 14 
（）・5ぢ （不明2例）
表10 v因子と制癌剤感受性
BLM CDDP 5-Fu 
＋ 計 ＋ 計 ＋ 計
v(+) 6 (50) 6 12 7 (58) 5 12 7 (78) 2 9 
v （ー） 3 (27) 8 11 2 (18) 9 11 1 (20) 4 5 
計 9 (39) 14 23 9 (39) 14 23 8 (73) 6 14 
く） =% （不明2例）
町ト ミ斗 ヘベ 1 50 男 高分化2 67 男 中分化
3 73 男 中分化
P<0.10 Pく0.05 4 76 男 中分化
t=2.174 DF=lO t=3.032 DF=B 5 74 男 低分化
6 67 男 中分化。
主癌 転移
7 63 男 高分化
病巣 リンパ節
中心部 辺縁部 8 44 男 中分化
図2 主癌病巣と転移リンパ節および腫腐の中心 9 66 男 低分化
部と辺縁部での CDDP感受性の相違 10 63 男 低分化
mg/kg静注では，食道0.21土0.0755μ,g/g，肺0.277
士0.0031 μg/g，肝 1.203±0. 2371 μg/g，胃 0.253土

















0. 35μg/g，食道では 4.3土1.2 μg/g，肺では 3.45土
0. 05μg/g，肝では 3.3±0. 7 μg/g，胃では 8.75土
3. 25μg/g，腎では 4.7土0.7 μg/gであった（図1).
表1 ヒト食道癌ヌード7 ウス移植例





















































































おり， 1例で変化を認めなかった CDDP lζ対して
66 日外宝第55巻第1号（昭和61年1月）
ug/g 5-Fu 2511g/kg I. P. 2 hrs後
10.0 
5.0 



















4 BLM 一「 十
COOP 
5 BLM ＋ 
CDDP 
榊 O.1 μ,g/ml (DNA合成能抑制70%以下）
+t 1. 0μ,g/ml (DNA合成能抑制7096以下）
+ 10 μ,g/ml (DNA合成能抑制707ぢ以下）





t=2.7＇即 DF=B NS 
t=0.752 DF=8 





















































































































4) CDDP 3mg/kg，または 5-Fu25mg/kg腹腔内
68 日外宝第55巻第1号（昭和61年 1月）
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